2/11
07:01 am
dtil
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
Low
Report
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
2/2
09:36 am
dtil
Registration for SOHO 2026 is now open; Register by June 10, 2026 to receive early registration rates [Yahoo! Finance]
Medium
Report
Registration for SOHO 2026 is now open; Register by June 10, 2026 to receive early registration rates [Yahoo! Finance]
1/12
08:55 am
dtil
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy [Yahoo! Finance]
Low
Report
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy [Yahoo! Finance]
1/12
07:01 am
dtil
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
Medium
Report
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
1/7
08:00 am
dtil
iECURE Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ECUR-506 for Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
Low
Report
iECURE Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ECUR-506 for Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
12/29
03:42 am
dtil
Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 [Seeking Alpha]
Low
Report
Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 [Seeking Alpha]
12/23
07:00 am
dtil
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
12/4
06:44 am
dtil
Precision Biosciences: Still Swinging And Finally Drawing Blood [Seeking Alpha]
Low
Report
Precision Biosciences: Still Swinging And Finally Drawing Blood [Seeking Alpha]
11/26
02:14 pm
dtil
Precision BioSciences (NASDAQ:DTIL) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Precision BioSciences (NASDAQ:DTIL) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
07:13 am
dtil
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 [Yahoo! Finance]
Medium
Report
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 [Yahoo! Finance]
11/19
07:01 am
dtil
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
Medium
Report
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025